Gene therapy for Bietti's crystalline dystrophy
Part of Eyes & vision clinical trials.
This trial tests a new gene therapy for Bietti's crystalline dystrophy, a rare inherited eye disease that causes progressive vision loss. The treatment aims to slow or stop vision loss by delivering a healthy gene to the eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of Bietti's crystalline dystrophy (BCD), a rare inherited eye condition.
- You must have genetic testing showing you have a mutation in the CYP4V2 gene.
- Your vision in the study eye must be significantly reduced, around 20/100 or worse.
- You must not have had gene therapy or stem cell therapy for BCD in the study eye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial offers compassionate use of the gene therapy ZVS101e for people with Bietti crystalline dystrophy (BCD) who were in the control group of an earlier study. It aims to give extended treatment access to those who didn't receive the experimental therapy before.
This study tests the safety of giving the same gene therapy to your second eye, after you already received it in one eye during an earlier study. It aims to see if it's safe and may help improve vision.
This early-phase trial tests a gene therapy called AXV-101 for children with vision loss caused by BBS1 genetic mutations. The goal is to see if it can help slow or stop retinal damage.
This trial tests a new gene therapy called ZVS106e for people with inherited retinal degeneration caused by changes in both copies of the ABCA4 gene. The therapy aims to slow or stop vision loss, and the study will check if it is safe and if it works.
This trial tests a new gene therapy called VG801 for people with Stargardt disease, a genetic condition that causes vision loss. The treatment aims to improve or slow vision loss by delivering a working copy of the ABCA4 gene to the retina.
This trial tests a gene therapy called OPGx-BEST1 injected under the retina to treat vision loss from Best vitelliform macular dystrophy or a related condition. It may help people with advanced disease who have a specific genetic change in the BEST1 gene.
Hear when a new Bietti's Crystalline Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.